Owner Scorecard


← All companies ← TBLA Manual TBRG → ← TAK Pharmaceuticals TEVA →

TBPH, Theravance Biopharma Inc.

Pharmaceuticals consumer brand Distress / turnaround

Theravance Biopharma Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines.

In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States ("US") Food and Drug Administration (the "FDA") approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease ("COPD").

In 2025, YUPELRI experienced net sales growth and reached launch-to-date highs in annual net sales and brand profitability.

Latest annual: FY2025 10-K
TBPH · Theravance Biopharma Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$107M
+66.9% YoY · 8% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $110M 5-yr avg $67M
Operating margin 1.2% 5-yr avg −163.8%
ROIC 0% 5-yr avg −45%
Owner-earnings margin 245% 5-yr avg −119%
Free cash flow margin 245% 5-yr avg −119%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is Collaboration Agreement (68%), Milestone (23%) and License (7%).
Situation
Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has run around −371% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 82% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −73%, above 15% in 0 of 10 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

Collaboration Agreement is 68% of revenue, with Milestone the other meaningful line at 23%.

Revenue by product line, FY2025
  • Collaboration Agreement68%$75M
  • Milestone23%$25M
  • License7%$8M
By geographyUnited States68%Europe30%

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMMar 2026
Income statement
$49M$15M$60M$73M$72M$55M$51M$57M$64M$107M$110MRevenueRevenue
174%621%161%144%151%180%131%122%107%69%67%SG&A / revenueSG&A/rev
291%n/m334%299%363%350%123%71%58%35%29%R&D / revenueR&D/rev
($180M)($260M)($239M)($252M)($298M)($258M)($92M)($56M)($47M)($4M)$1MOperating incomeOp. inc.
−371.0%n/m−395.5%−343.1%−414.2%−466.1%−179.1%−97.6%−72.9%−3.4%1.2%Operating marginOp. mgn
($191M)($285M)($216M)($236M)($278M)($199M)$872M($55M)($56M)$106M$115MNet incomeNet inc.
0%18%16%Effective tax rateTax rate
Cash flow & returns
($99M)($201M)($113M)($238M)($250M)($208M)($187M)($27M)($12M)$239M$269MOperating cash flowOp. cash
$3M$4M$3M$3M$3M$4M$3M$2M$2M$2M$2MDepreciationDeprec.
$47M$31M$48M($65M)($39M)($74M)($1.1B)$925K$22M$113M$135MWorking capital & otherWC & other
$2M$2M$7M$3M$7M$3M$572K$2M$332K$42K$42KCapexCapex
4.4%15.6%12.0%4.3%9.2%6.2%1.1%4.3%0.5%0.0%0.0%Capex / revenueCapex/rev
($101M)($203M)($116M)($241M)($254M)($211M)($188M)($29M)($12M)$238M$269MOwner earningsOwner earn.
−207.9%n/m−192.2%−328.8%−353.1%−382.0%−365.3%−50.3%−18.4%221.9%244.8%Owner earnings marginOE mgn
($101M)($203M)($120M)($241M)($257M)($211M)($188M)($29M)($12M)$238M$269MFree cash flowFCF
−207.9%n/m−199.0%−328.8%−357.7%−382.0%−365.3%−51.3%−18.4%221.9%244.8%Free cash flow marginFCF mgn
$129M$197M$445KBuybacksBuybacks
-62%-82%-762%-115%-101%-108%-64%-26%-27%-2%0%ROICROIC
-54%-248%197%-26%-32%36%39%Return on equityROE
−54%−248%197%−26%−32%36%39%Retained to equityRetained/eq
Balance sheet
$345M$89M$378M$58M$81M$90M$298M$40M$38M$168M$288MCash & investmentsCash+inv
$646K$2M$620K$87KReceivablesReceiv.
$12M$17M$0$0InventoryInvent.
$2M$6M$9M$5M$7M$3M$2M$2M$2M$3M$1MAccounts payablePayables
$11M$13M($8M)($1M)Operating working capitalOper. WC
$529M$379M$533M$338M$393M$250M$353M$134M$161M$418M$418MCurrent assetsCur. assets
$49M$63M$99M$112M$124M$59M$29M$25M$32M$38M$32MCurrent liabilitiesCur. liab.
10.7×6.1×5.4×3.0×3.2×4.3×12.3×5.4×5.0×10.9×13.1×Current ratioCurr. ratio
$639M$441M$560M$409M$469M$375M$607M$382M$354M$486M$472MTotal assetsAssets
$223M$224M$454M$455M$619M$616M$0$229MTotal debtDebt
($122M)$135M$76M$397M$538M$526M($40M)($60M)Net debt / (cash)Net debt
-128.5×-30.4×-22.8×-7.9×-34.8×-30.2×-14.4×-23.8×-18.4×-1.5×0.5×Interest coverageInt. cov.
$350M$115M($52M)($224M)($304M)($339M)$442M$213M$176M$297M$291MShareholders’ equityEquity
84.6%319.4%85.0%82.3%87.6%112.2%77.4%44.2%33.2%17.2%16.5%Stock comp / revenueSBC/rev
Per share
44.7M52.4M54.0M55.6M62.3M69.5M73.6M55.3M48.8M51.5M51.3MShares out (diluted)Shares
$1.09$0.29$1.12$1.32$1.15$0.80$0.70$1.04$1.32$2.09$2.14Revenue / shareRev/sh
$-4.26$-5.45$-3.99$-4.25$-4.46$-2.87$11.85$-1.00$-1.15$2.06$2.23EPS (diluted)EPS
$-2.26$-3.89$-2.15$-4.34$-4.07$-3.04$-2.55$-0.52$-0.24$4.63$5.24Owner earnings / shareOE/sh
$-2.26$-3.89$-2.23$-4.34$-4.12$-3.04$-2.55$-0.53$-0.24$4.63$5.24Free cash flow / shareFCF/sh
$0.05$0.05$0.13$0.06$0.11$0.05$0.01$0.04$0.01$0.00$0.00Cap. spending / shareCapex/sh
$7.83$2.20$-0.96$-4.03$-4.87$-4.87$6.00$3.85$3.59$5.76$5.67Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+7.5%/yr+12.6%/yr
Capital spending / share−36.4%/yr−62.2%/yr
Book value / share−3.4%/yr

The record, charted

FY2016–2025

Each measure over its full record; the current point and the worst year marked.

Share count
52Mpeak FY2022
ROIC
−2%low FY2018

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

$238Mowner earningsvs.$106Mnet incomelow FY2020

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned $106M of profit into $238M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

Reported net income$106M
Owner earnings$238M · 222% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income$106M($56M)($55M)$872M($199M)
Depreciation & amortizationnon-cash charge added back+$2M+$2M+$2M+$3M+$4M
Stock-based compensationreal costnon-cash, but a real cost+$18M+$21M+$25M+$40M+$62M
Working capital & othertiming of cash in and out, other non-cash items+$113M+$22M+$925K−$1.1B−$74M
Cash from operations$239M($12M)($27M)($187M)($208M)
Maintenance capital expenditurethe spending needed just to hold position and volume−$42K−$332K−$2M−$572K−$3M
Owner earnings$238M($12M)($29M)($188M)($211M)
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$588K
Free cash flow$238M($12M)($29M)($188M)($211M)
Owner-earnings marginowner earnings ÷ revenue222%-18%-50%-365%-382%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $18M), owner earnings is nearer $220M.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($4M) ÷ interest expense $2M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net debt against an operating loss
    Cash $168M − debt $228M
    What this means

    Netting $168M of cash and short-term investments against $228M of debt leaves $60M owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Negative, funded by others
    DSO 2 + DIO 0 − DPO 155 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money. (Little or no inventory, a services / asset-light model, so the inventory leg is ~0.)

Is it a good business?

  • Below average through the cycle
    10-yr median, range -762%–-2%; -1% latest = NOPAT ($3M) ÷ invested capital $357M
    Industry peers: median -38%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran -1% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Positive this year, negative across the cycle
    latest $238M = operating cash $239M − maintenance capex $42K (positive this year), after an earlier loss stretch (10-yr median -329%)
    Industry peers: median -142%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 222% of revenue this year, a -329% median across 10 years. Treating stock comp as the real expense it is (less $18M of SBC) leaves $220M.

  • Cash-backed
    Cash from ops $239M ÷ net income $106M
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks $445K ÷ Owner Earnings $238M
    What this means

    Of $238M Owner Earnings, $445K (0%) went back to shareholders, $0 dividends, $445K buybacks. But the buybacks barely exceed stock issued to employees ($18M SBC), net of dilution, little was truly returned. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 0.03×
    Harvesting
    Capex $42K ÷ depreciation $2M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 2 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $107M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 10.93×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $228M vs $380M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 8 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.04/share (latest year $2.05), the averaged base the calculator's gate runs on, and book value is $5.76/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 2 of 10
    What this means

    Lost money in 8 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 7 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −819% → −58% (3-yr avg ends)

    In the filing’s words The words confirm the number: the filing says price increases held their volume, and the margin widened with them — Buffett’s strongest mark of pricing power.

    What this means

    Through the cycle the operating margin widened — about −819% early to −58% lately, median −371% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2017 · −1690.6% op. margin
    What this means

    Operations went underwater in 2017, understand why before trusting the good years.

  • Share count +1.6%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Raised, but not as a competitor

The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$418M
  • Cash & short-term investments$288M
  • Receivables$87K
  • Other current assets$129M
Current liabilities$32M
  • Accounts payable$1M
  • Other current liabilities$31M
Current ratio13.14×all current assets ÷ what's due · Graham looked for 2×
Quick ratio13.14×stricter: inventory excluded
Cash ratio9.07×strictest: cash alone against what's due
Working capital$386Mthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+15.0%the freshest read on whether the business is still growing
Current ratio, recent quarters5.2× → 13.1×
Deeper floors
Tangible book value$291Mequity stripped of goodwill & intangibles
Debt incl. operating leases$41M$41M of it operating leases
Deferred revenue$199Kcustomer cash collected before delivery; operating float

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2023Rick E Winningham$4.3M$4.1M($29M)
2024Rick E Winningham$4.0M$2.1M($12M)
2025Rick E Winningham$1.5M$7.7M$238M

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Stock-based compensation$18M

    The slice of the business handed to employees in shares this year, 17% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Inverting the record

Invert: instead of why Theravance Biopharma Inc. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.

None of the 3 tests turned up a mark; each came back clean. A clean panel says only that these particular ways of being wrong are not written into the record.

Each test came back clean
  • Did debt outgrow the business?
  • Did receivables and inventory outpace sales?
  • Are "one-time" charges a yearly habit?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Income taxes, Stock compensation as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
XNCRXencor Inc.$126M-69.2%-12%-30%
GYREGyre Therapeutics Inc.$117M96%-276.4%-9%-1120%
URGNUroGen Pharma Ltd.$110M-157.5%-58%-142%
TBPHTheravance Biopharma Inc.$107M94%-357.1%-73%-268%
ZVRAZevra Therapeutics Inc.$106M-158.4%-127%-123%
ZYMEZymeworks Inc.$106M-180.7%-38%-153%
GRCEGrace Therapeutics Inc.$100M100%-11.1%-19%-9%
SPRYARS Pharmaceuticals Inc.$84M-353.3%-39%-320%
Group median96%-169.5%-38%-148%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Theravance Biopharma Inc. has delivered.

$
Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings $269M on 52M shares outstanding, per the 10-Q cover, as of 2026-04-30; net cash $60M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Theravance Biopharma Inc. (TBPH), the owner's record," https://ownerscorecard.com/c/TBPH, data as of 2026-07-09.

Manual order: ← TBLA its page in the Manual TBRG →

Industry order: ← TAK the Pharmaceuticals chapter TEVA →